ICPT 19 (+0%)
US45845P1084BiotechnologyBiotechnology

Intercept Pharmaceuticals (ICPT) Stock Highlights

19 | +0%
2023-12-14 01:26:13
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Statistics

Range Today
19 19
Volume Today 0
Range 1 Year
8.82 21.86
Volume 1 Year 313.57M
Range 3 Year
8.82 39.2
Volume 3 Year 790.69M
Range 10 Year
8.82 497
Volume 10 Year 1.94B

Highlights

Market Capitalization 794.69M (small)
Floating Shares 34.49M
Current Price 19
Price To Earnings -17.43
Price To Revenue 2.19
Price To Book 11.06
Earnings Per Share -1.09
Payout Ratio 0%

Performance

Latest 0%
1 Month +2.43%
3 Months +85.19%
6 Months +18.75%
1 Year +18.09%
3 Years -51.08%
5 Years -80.3%
10 Years -61.22%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.